興達國際(01899.HK)附屬擬認購1587萬股貴州輪胎(000589.SZ)A股股份
格隆匯3月4日丨興達國際(01899.HK)公佈,於2021年3月4日,公司附屬江蘇興達與貴州輪胎訂立認購協議,內容有關江蘇興達認購將由貴州輪胎根據非公開發售發行的1587萬股A股(即非公開發售股份),認購價為現金每股人民幣6.30元,認購股份總代價為人民幣1億元。
認購股份佔貴州輪胎於本公佈日期已發行股本約2.0%。假設貴州輪胎根據非公開發售發行全部1.59億股A股,則認購股份佔貴州輪胎經非公開發售擴大已發行股本約1.7%。
董事認為通過認購A股投資貴州輪胎,集團可改善其投資回報及為公司股東創造更大價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.